Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E49.94 EPS (ttm)1.77 Insider Own2.30% Shs Outstand341.07M Perf Week-8.49%
Market Cap30.15B Forward P/E6.57 EPS next Y13.46 Insider Trans-14.16% Shs Float335.77M Perf Month3.33%
Income605.10M PEG2.41 EPS next Q2.60 Inst Own66.80% Short Float3.60% Perf Quarter12.03%
Sales9.99B P/S3.02 EPS this Y198.90% Inst Trans20.69% Short Ratio1.28 Perf Half Y-64.09%
Book/sh18.39 P/B4.81 EPS next Y31.10% ROA1.50% Target Price156.67 Perf Year-47.23%
Cash/sh4.16 P/C21.23 EPS next 5Y20.70% ROE9.90% 52W Range69.33 - 263.81 Perf YTD-13.04%
Dividend- P/FCF14.51 EPS past 5Y19.20% ROI8.40% 52W High-66.49% Beta0.65
Dividend %- Quick Ratio1.20 Sales past 5Y58.70% Gross Margin75.00% 52W Low27.49% ATR7.05
Employees16800 Current Ratio1.50 Sales Q/Q35.50% Oper. Margin19.20% RSI (14)47.16 Volatility7.11% 7.80%
OptionableYes Debt/Eq4.87 EPS Q/Q-82.70% Profit Margin6.10% Rel Volume0.56 Prev Close83.44
ShortableYes LT Debt/Eq4.76 EarningsFeb 22 Payout0.00% Avg Volume9.47M Price88.39
Recom2.20 SMA20-2.78% SMA50-8.36% SMA200-49.15% Volume5,312,354 Change5.93%
Jan-07-16Reiterated Mizuho Neutral $130 → $112
Jan-06-16Resumed Susquehanna Neutral $105
Dec-17-15Downgrade Mizuho Buy → Neutral $111 → $130
Dec-14-15Reiterated RBC Capital Mkts Outperform $206 → $194
Nov-30-15Resumed CIBC Sector Perform
Nov-20-15Reiterated Mizuho Buy $155 → $111
Nov-17-15Reiterated Morgan Stanley Equal-Weight $200 → $98
Nov-11-15Reiterated Stifel Buy $285 → $200
Nov-11-15Reiterated RBC Capital Mkts Outperform $213 → $206
Nov-11-15Reiterated JP Morgan Overweight $265 → $225
Nov-06-15Reiterated Guggenheim Buy $300 → $195
Nov-03-15Reiterated RBC Capital Mkts Outperform $231 → $213
Nov-02-15Reiterated Jefferies Buy $224 → $172
Nov-02-15Downgrade Goldman Buy → Neutral
Oct-30-15Reiterated UBS Buy $285 → $255
Oct-27-15Upgrade Mizuho Neutral → Buy $155
Oct-27-15Reiterated RBC Capital Mkts Outperform $250 → $231
Oct-27-15Reiterated Barclays Overweight $300 → $135
Oct-20-15Downgrade CIBC Sector Outperform → Sector Perform
Oct-09-15Initiated Mizuho Neutral
Feb-12-16 05:31PM  Express Scripts Giving 'Extra Scrutiny' to Valeant Prescriptions at Bloomberg +5.93%
03:50PM  Munger on IBM, Life Advice, Why Valeant Comments Brought 'Nothing But Trouble'
03:49PM  A gold pile-on is coming, and nine other money stories you may have missed at MarketWatch
12:56PM  Five Foreign Stocks Hedge Funds Love at Insider Monkey
11:50AM  Charlie Munger At The 2016 Daily Journal Corporation Meeting [FULL NOTES AND AUDIO]
11:11AM  Inside the M&A Deals in the Health-Care Sector
10:14AM  How Hedge Fund Crowding Dragged Down Tableau Software
07:03AM  Valeant uses rare accounting maneuver for acquisitions that cushions income at MarketWatch
Feb-11-16 03:31PM  Morgan Stanley is Wrong: This Biotech is Ready to Explode Higher
03:23PM  One Reason Why Valeant (VRX) Stock Is Retreating Today at TheStreet
03:01PM  Why You Are a Better Investor Than Bill Ackman at Fortune
12:57PM  Valeant Pharmaceuticals Extends Recent Slide at The Wall Street Journal
09:12AM  How Hedge Fund Crowding Dragged Down Transdigm
Feb-10-16 06:09PM  Bill Ackmans Pershing Square slides 8.2% in February at MarketWatch
05:37PM  Bill Ackman's Pershing Square falls 8.2% in February at MarketWatch
05:34PM  Bill Ackman is getting annihilated
03:12PM  Bill Ackman's 2 Best Investments (GGP, CP) at Investopedia
02:59PM  Munger Says Couldn't Resist Valeant Critique That Caused Trouble
02:59PM  [$$] Three Best Buys in Specialty Pharma at Barrons.com
01:55PM  Relypsa: This Biotech Just Released Stunning Data
11:22AM  SEC Investigating Ex-Salix Executives Over Misleading Investors
08:30AM  Who Will Come Out On Top As Flu Season Draws Down Accesswire
Feb-09-16 06:15PM  SEC investigating former Salix Pharma execs, Reuters reports at bizjournals.com
03:14PM  Heres What Wall Street Thinks of Bill Ackmans New Herbalife Attack at Fortune
02:21PM  SEC probes former Salix CEO, CFO over investor disclosure-source Reuters
02:16PM  3 Reasons Valeant Pharmaceuticals Intl. Inc. Was Clobbered in January at Motley Fool
09:56AM  OICisDifferent: The Drug Behind The Super Bowl 50 Constipation Ad at Forbes
01:00AM  Pharming and Cytobioteck Announce Extension of Distribution Agreement for RUCONEST® PR Newswire
Feb-08-16 05:36PM  CANADA STOCKS-TSX falls, pressured by financial and energy stocks -7.21%
01:35PM  Pharma's Unflattering Super Bowl at Bloomberg
12:18PM  Billionaire Bill Ackman Buys More Valeant Shares, Starboard Value Gradually Jettisons Darden Restaurants Inc. (DRI) Stake and Two Other Moves at Insider Monkey
08:12AM  Valeant Pharmaceuticals International, Inc. breached its 50 day moving average in a Bearish Manner : February 8, 2016
08:06AM  Why Does Valeants Valuation Seem to Be at a Discount?
Feb-07-16 04:25PM  Lou Simpson Adds to Valeant Stake
02:45PM  5 Trade ideas for Monday: JP Morgan, Norfolk Southern, P&G, Raytheon and Valeant
Feb-05-16 05:14PM  Congress unites in scorn for Shkreli, but gridlock remains
04:46PM  The Real Lesson of the Shkreli Circus at Bloomberg
03:10PM  Valeant's Share Price Continues to Decline
12:25PM  Shkreli theatrical display misses core biotech pricing issues
12:13PM  CRI Advanced Hound Partners in January. VRX dragged
11:04AM  So, Bill Ackman Makes Some Good Points on the Index Bubble...
12:45AM  [$$] Valeant Needs More Volume Amid the Noise at The Wall Street Journal
12:44AM  [$$] Martin Shkreli Pleads the Fifth Before Congress at The Wall Street Journal
Feb-04-16 08:06PM  [$$] Martin Shkreli Takes the Fifth Before Congress at The Wall Street Journal
04:44PM  After The Martin Shkreli Circus, How Can We Fix Drug Pricing? at Forbes
03:15PM  [$$] Valeant Needs More Volume Amid the Noise at The Wall Street Journal
03:04PM  Rep. John Mica: Shkreli Was Arrogant at Bloomberg
02:29PM  The Secrets Out: Its Time to Buy This Biotech Gem
01:54PM  Shkreli, Valeant Go To Washington -- Recap at The Wall Street Journal
01:31PM  Smirks, silence and nerves: Recap of the drug pricing hearing with Shkreli at MarketWatch
12:35PM  How Martin Shkreli Is Trashing the Pharma Industry at Fortune
11:06AM  TW Drove ValueActs Performance in January. VRX did not
10:07AM  Expectations for Valeant Pharmaceuticals in 2016
09:38AM  Valeant, Turing Slammed as Shkreli Calls Congress Imbeciles at Bloomberg
09:38AM  Valeant, Turing Slammed as Shkreli Calls Congress Imbeciles
09:28AM  Martin Shkreli could not stop laughing during his testimony to Congress
09:08AM  VALEANT TO CONGRESS: It is actually a good thing we jack up drug prices
08:07AM  Valeant Pharmaceuticals: The Near-Term Growth Prospects
12:10AM  [$$] Valeants Interim CEO to Seek Change to Rules for Prescription Assistance at The Wall Street Journal
Feb-03-16 06:46PM  [$$] Valeant's Interim CEO to Seek Change to Rules for Prescription Assistance at The Wall Street Journal
06:38PM  Valeant just put out the last kind of statement a company wants to before a congressional hearing
05:46PM  Why Did Valeant Shares Fall after Strong 3Q15 Results?
05:46PM  Valeant Pharmaceuticals: The Expectations for 4Q15 Earnings
05:07PM  Price Hike on $750 Pill Was Shkreli's, Turing Tells Congress at Bloomberg
01:08PM  Martin Shkreli Seriously Didnt Care About Jacking Up Drug Prices at Fortune
10:45AM  Canada Stocks Rebound to Snap Two-Day Slide as Commodities Gain at Bloomberg
10:34AM  $1bn here we come. Martin Shkreli told Turing board as Daraprim buy got closer at MarketWatch
10:19AM  Shkreli May Not Talk Drug Pricing Before Congress But His Memos Say Plenty at Forbes
10:14AM  Bill Ackman Is Right About Index Funds at Forbes
09:01AM  Yahoo, Drugs and Argentina
09:01AM  Headline Risk Is Poison for Pharma and Biotech
07:59AM  Sen. Ted Cruz Wants To Change The Way The FDA Approves Drugs at Forbes
12:26AM  [$$] Valeant, Turing Boosted Drug Prices to Fuel Preset Profits at The Wall Street Journal
Feb-02-16 10:58PM  [$$] Valeants Sales Growth: Is It Price or Volume? at The Wall Street Journal
06:30PM  Valeant Interim CEO Schiller to Be Paid $400,000 a Month at Bloomberg
05:30PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial
03:31PM  Pharma firm records shed light on price hikes at USA TODAY
03:21PM  Under Pressure: Eyeing Pershing Square's Holdings at Investopedia
02:42PM  Documents detail price hike decisions by Turing, Valeant
02:06PM  Documents show profit-seeking behind price hikes at Turing, Valeant Reuters
01:26PM  Why Valeant (VRX) Stock Is Lower Today at TheStreet
12:51PM  Valeant Trends Down Following Oversight Committee Release Of Docs
12:05PM  A government document dump just confirmed the ugliest things Wall Street didn't want to believe about Valeant
11:34AM  Valeant's Sales Growth: Driven by Price Increases or Volume Growth? at The Wall Street Journal
11:32AM  [$$] Price of Valeant drug targeted in Clinton campaign was raised by 356% at Financial Times
11:15AM  House committee releases documents on Valeant's drug pricing at MarketWatch
11:03AM  Newly released documents show profit-seeking behind price hikes at Turing, Valeant Reuters
10:28AM  Valeant, Turing Focused on Profit First, Congress Says at Bloomberg
Feb-01-16 04:34PM  IPO's Go Into Deep Freeze, as Twitter Gets Hot -- Podcast at The Wall Street Journal +6.02%
03:09PM  Study Says This Cold Medicine Doesnt Actually Fight Colds at Fortune
09:21AM  [$$] Investors face reckoning over debt bloated deals at Financial Times
05:46AM  PRESS DIGEST- Canada- Feb 1 Reuters
Jan-31-16 06:24AM  Is This Person the Next Warren Buffett? at Motley Fool
Jan-30-16 07:00AM  Bill Ackman actually had a point with his index fund bubble theory at MarketWatch
Jan-29-16 07:28PM  Clinton's Price-Gouging Complaint Sidesteps Generic Drug Problem at Bloomberg
03:45PM  Express Scripts drops coverage of Valeant diabetes drug Glumetza Reuters
02:16PM  One of the biggest healthcare companies in America fired a warning shot at Valeant
01:33PM  Valeant Pharmaceuticals (VRX) Surges After Defending Drug Price Hike at TheStreet
01:03PM  Express Scripts Calls Out Valeant, Says It's 'Holding Pharmaceutical Manufacturers Accountable For Excessive Price Hikes'
12:31PM  Pershing Square's New Presentation, Part 1
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pearson J. MichaelChief Executive OfficerNov 05Sale78.481,297,399101,825,9701,514,664Nov 09 05:24 PM
Farmer Ronald HaroldDirectorOct 21Buy181.601,500272,39515,532Oct 22 05:09 PM
Farmer Ronald HaroldDirectorAug 26Buy220.00500110,0002,000Aug 27 04:33 PM
Farmer Ronald HaroldDirectorAug 21Buy224.971,000224,9731,500Aug 25 04:47 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 31Buy257.25704181,104441,675Aug 03 04:54 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 30Buy253.997,1711,821,362440,971Aug 03 04:54 PM
Rosiello Robert L.Executive Vice PresidentJun 12Buy232.5112,9002,999,37912,900Jun 16 04:01 PM
UBBEN JEFFREY WDirectorJun 10Sale220.244,200,000925,011,6131,059,793Jun 12 07:23 PM
Farmer Ronald HaroldDirectorJun 09Buy232.05500116,025500Jun 10 05:02 PM
Farmer Ronald HaroldDirectorJun 08Buy289.20500144,60035,426Jun 10 05:02 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Option Exercise51.0114,900760,04951,575Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Sale238.0037,9009,020,31813,675Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Option Exercise51.011005,10136,775Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Sale240.0010024,00036,675Jun 03 05:45 PM
Whitaker Anne ClemDirectorMay 26Buy234.677,5001,760,0007,500May 27 04:29 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 05Option Exercise6.1021,807133,02364,994May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Option Exercise25.4290,9382,311,644134,125May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Sale222.5490,93820,237,44343,187May 06 05:51 PM
Kornwasser LaizerEVP, Company Group ChairmanApr 17Option Exercise0.0045,0000123,377Apr 21 05:46 PM
Mirovsky PavelPresident, EMENAApr 15Option Exercise0.0024,175034,175Apr 17 05:28 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 03Option Exercise6.1021,808133,02943,187Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Option Exercise25.4290,9392,311,669112,296Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Sale200.0190,93918,189,09121,379Mar 04 05:24 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMEAFeb 27Option Exercise0.0010,000010,000Mar 02 05:16 PM